Prognostic value of circulating tumor DNA fraction (TF) for patients with metastatic renal cell carcinoma (mRCC).

Amado J. Zurita,Natalie Danziger,Takara Scott,Ole Gjoerup,Lei Zhong,Hanna Tukachinsky,Jeffrey S. Ross,Ryon Graf

DOI: https://doi.org/10.1200/jco.2024.42.4_suppl.455

IF: 45.3

2024-02-01

Journal of Clinical Oncology

Abstract:455 Background: Risk stratification, based on the IMDC classification, is central to treatment decisions for patients with mRCC. The strongest prognostic feature in the original validation was the clinical assessment of patient frailty through performance status (PS). Although inexpensive and ubiquitous, clinical features such as PS are prone to degrees of subjectivity and considerable variation in assessment from practitioner to practitioner. Recent work (Reichert et al. 2022, Annals of Oncology) observed that TF levels around the initiation of new treatment were prognostic independently of standard clinical features including ECOG PS, in advanced/metastatic lung, breast, prostate, and colorectal cancers, but has not yet been investigated in mRCC. Methods: This study used a cohort of patients in the de-identified nationwide, U.S. based Flatiron Health-Foundation Medicine renal cell clinico-genomic database, which originated from approximately 280 US cancer clinics (~800 sites of care), who underwent genomic testing as part of routine care. TF estimation on FoundationOne Liquid CDx was based on a composite algorithm incorporating multiple factors including aneuploidy and variant allele frequency of canonical alterations. Clinical characteristics, laboratory and treatment data were captured from the electronic health record. Real-world progression-free survival (rwPFS) and overall survival (rwOS) were evaluated by TF level. Results: 45 patients with mRCC and liquid biopsy testing had TF assessments within 90 days of start of new treatment. Patients with TF≥1% (15 of 45) had younger median age (58y vs. 66y, p = 0.041) and higher prevalence of calcium levels above upper limit of normal (46% vs. 4%, p < 0.001). Higher TF (≥1%) was associated with less favorable rwPFS (hazard ratio (HR) 1.41, 0.70-2.82, p=0.34) and rwOS (HR 2.54, 1.08-5.96, p=0.033). In the 15 patients with TF ≥1%, we observed detection of known pathogenic genomic alterations in VHL (7/15, 47%), SETD2 (4/15, 27%), PBRM1 (4/15, 27%), BAP1 (3/15, 20%). Conclusions: In this initial cohort study, ctDNA TF shows prognostic significance in mRCC with potential to inform expected longevity of patients. Liquid biopsy detects alterations characteristic of mRCC genomics, supporting its utility to identify drivers and potential targetable alterations. Risk stratification based entirely upon algorithmic determination independent of human interpretation has the potential to improve risk stratification in mRCC and improve treatment decisions. Expansion of our cohort and survival data maturation will allow for evaluation of whether TF may be a useful addition to the established IMDC clinical classification and improve risk stratification and treatment assignment.

oncology